Fast Five Quiz: Can You Treat Waldenström Macroglobulinemia?

Emmanuel C. Besa, MD


March 22, 2022

The final updated ESMO guideline requests that clinicians strongly encourage their patients with WM to enroll in clinical trials, regardless of disease stage and line of treatment.

Clinicians should aim to follow the recommendations set forth in the ESMO guidelines, which are applicable for use worldwide.

Although hyperviscosity is a presentation of WM and must be urgently treated, chemoimmunotherapy regimens and other therapies are important to stabilize WM.

Learn more about current recommendations from the ESMO guideline.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.